X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Product Name: XEN1101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $345.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 04, 2023
Details:
The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Product Name: XEN1101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 29, 2023
Details:
The net proceeds woll be used for the clinical development of company's XEN1101, a differentiated Kv7 potassium channel opener, as well as other programs entering clinical development and to fund its pre-clinical and discovery activities.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Product Name: XEN1101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $225.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 29, 2023
Details:
XEN1101 is a differentiated Kv7 potassium channel opener which is being evaluated under phase 2 clinical trials for the treatment of major depressive disorder (MDD).
Lead Product(s): XEN1101
Therapeutic Area: Psychiatry/Psychology Product Name: XEN1101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
NBI-921352, an investigational, selective sodium channel 1.6 inhibitor (Nav1.6) currently under development in adult patients with focal onset seizures (FOS), failed to demonstrate meaningful reduction in seizure frequency.
Lead Product(s): NBI-921352
Therapeutic Area: Rare Diseases and Disorders Product Name: NBI-921352
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Neurocrine Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
XEN1101 is a differentiated Kv7 potassium channel opener administered as an adjunctive treatment for adult patients with focal epilepsy,being developed for the treatment of epilepsy and major depressive disorder.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Product Name: XEN1101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
New XEN1101 Phase 2b X-TOLE sub-group analysis demonstrates statistically significant efficacy results at all doses at Week 1, differentiating XEN1101 with rapid onset to seizure reduction.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Product Name: XEN1101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the DBP of XEN1101 compared to placebo.
Lead Product(s): XEN1101
Therapeutic Area: Neurology Product Name: XEN1101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
XEN1101, a KCNQ channel opener, has been studied in Phase 2b clinical trial in adult patients demonstrated compelling efficacy results, with a statistically significant and dose-dependent reduction from baseline in monthly focal seizure frequency when compared to placebo.
Lead Product(s): XEN1101
Therapeutic Area: Psychiatry/Psychology Product Name: XEN1101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
Xenon has an ongoing collaboration with Neurocrine Biosciences to develop treatments for epilepsy. Neurocrine Biosciences has an exclusive license to XEN901, now known as NBI-921352, a selective Nav1.6 sodium channel inhibitor.
Lead Product(s): NBI-921352
Therapeutic Area: Neurology Product Name: NBI-921352
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: $15.0 million Upfront Cash: $6.7 million
Deal Type: Collaboration January 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
